Schisanhenol suppresses cytokine storm and acute lung injury in mice

FHS
March 7, 2024
3:35 am

Cytokine storm (CS) is an acute systemic inflammatory response with limited effective interventions up to now.

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option.

January 27, 2024

Frontline Combo Yields High Remission Rate in Hairy Cell Leukemia

Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy

September 26, 2023

Inaccurate data stalls pediatric equity initiatives

Leaders at three Michigan hospitals aiming to address equity issues for pediatric patients wanted to start with inspecting data key to identifying potential inequities.

September 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.